Targeted pharmaceutical composition for treating lung cancer
Through the combination of pyrrolitinib and erdatinib, the phosphorylation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells was suppressed, and the problem of limited efficacy of pyrrolitinib monotherapy was solved, and the HER2-positive non-small cell treatment was achieved Effective treatment of lung cancer.
Patent Information
- Application Number
- CN202411278474.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-08
AI Technical Summary
The existing single-agent pyrrolitinib treatment of HER2-positive non-small cell lung cancer has limited efficacy and lacks effective combined treatment strategies.
Develop a targeted pharmaceutical composition containing pyrrolitinib and erdatinib with a molar ratio of 1:1 to 1.25, which enhances the phosphorylation of pyrrolitinib by inhibiting the phosphorylation of FGFR3 receptor in HER2-positive non-small cell lung cancer cells. Sensitivity and synergistically inhibit lung cancer cell proliferation and tumor growth.
It significantly improved the sensitivity of HER2-positive non-small cell lung cancer cells to pyrrolitinib, enhanced the inhibitory effect on tumors, and showed better efficacy in the treatment of HER2-positive non-small cell lung cancer.
Smart Images

Figure CN118903138A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a targeted drug composition for treating lung cancer, and belongs to the technical field of biomedicine. Background Art
[0002] Lung cancer is a malignant tumor that originates from the trachea, bronchial mucosa or glands. Lung cancer is divided into non-small cell lung cancer (NSCLC, accounting for about 85%) and small cell lung cancer (accounting for about 15%) according to histopathology, while the WHO further divides non-small cell lung cancer into three main types: squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Through genetic testing of patients with non-small cell lung cancer, mutations, amplifications and overexpression of genes such as EGFR, ALK, ROS, BRAF, HER2 and MET were found. Personalized targeted treatment for different genotypes can significantly improve the prognosis and quality of life of lung cancer patients.
[0003] Human epidermal growth factor receptor 2 (HER2) is a member of the human epidermal growth factor receptor (EGFR) family. Studies have confirmed that the HER2 gene is one of the mutation-driven genes in non-small cell lung cancer. About 2-3% of non-small cell lung cancers have HER2 gene mutations, and about 2.5% of non-small cell lung cancers have HER2 gene amplification and overexpression. In addition, studies have shown that HER2 positivity is associated with higher tumor grade and a higher risk of recurrence and death. Currently, there is no standard treatment recommended by clinical guidelines for HER2-positive non-small cell lung cancer.
[0004] Pyrotinib was approved for marketing by the National Medical Products Administration (NMPA) in 2018 for use in combination with capecitabine to treat patients with HER2-positive breast cancer. Phase II clinical studies NCT02834936 and ChiCTR1800020262 both evaluated the efficacy of pyrotinib monotherapy in patients with HER2-mutated advanced lung adenocarcinoma, with objective response rates (ORR) of 30.0% and 19.2%, respectively, median progression-free survival (mPFS) of 6.9 and 5.6 months, and median overall survival (OS) of 14.4 and 10.5 months, respectively. At the same time, clinical data at this stage show that pyrotinib has certain anti-tumor activity against HER2-positive non-small cell lung cancer. However, further studies have shown that the efficacy of pyrotinib monotherapy in the second and later lines of HER2-positive non-small cell lung cancer is relatively limited.
[0005] In order to overcome the limitations of pyrotinib alone in the treatment of HER2-positive non-small cell lung cancer, in recent years, a number of clinical trials on the combination of pyrotinib and other drugs for the treatment of HER2-positive non-small cell lung cancer are being carried out, such as NCT04447118 and NCT04144569, but their efficacy is still unclear. Therefore, it is urgent to develop more drug combination treatment strategies based on pyrotinib that can effectively treat HER2-positive non-small cell lung cancer. At this stage, there are no reports on the combination of pyrotinib and erdafitinib to improve the efficacy of pyrotinib in HER2-positive non-small cell lung cancer. Summary of the invention
[0006] To solve the above problems, the present invention provides a targeted pharmaceutical composition for preventing and / or treating lung cancer, wherein the components of the targeted pharmaceutical composition include pyrotinib and erdafitinib.
[0007] In one embodiment of the present invention, in the targeted drug composition, the molar ratio of pyrotinib to erdafitinib is 1:1 to 1.25.
[0008] In one embodiment of the present invention, in the targeted drug composition, the molar ratio of pyrotinib to erdafitinib is 1:1.25.
[0009] In one embodiment of the present invention, the lung cancer includes non-small cell lung cancer; the non-small cell lung cancer includes HER2-positive non-small cell lung cancer.
[0010] In one embodiment of the present invention, the prevention and / or treatment of lung cancer includes increasing the sensitivity of lung cancer cells to pyrotinib, inhibiting the proliferation of lung cancer cells and / or inhibiting the growth of lung tumors.
[0011] In one embodiment of the present invention, the increasing the sensitivity of lung cancer cells to pyrotinib comprises inhibiting the activation of FGFR3 receptors in lung cancer cells; the inhibiting the activation of FGFR3 receptors in lung cancer cells comprises inhibiting the activation of FGFR3 receptors in lung cancer cells by inhibiting the phosphorylation of FGFR3 receptors in lung cancer cells.
[0012] In one embodiment of the present invention, the lung cancer cells include non-small cell lung cancer cells; the non-small cell lung cancer cells include HER2-positive non-small cell lung cancer cells; the lung tumors include tumors of non-small cell lung cancer; the lung tumors of non-small cell lung cancer include tumors of HER2-positive non-small cell lung cancer.
[0013] In one embodiment of the present invention, the HER2-positive non-small cell lung cancer cells include H2170 cell line and / or Calu-3 cell line.
[0014] In one embodiment of the present invention, the ingredients of the targeted drug composition include active components and pharmaceutical excipients; the active components consist of pyrotinib and erdafitinib.
[0015] In one embodiment of the present invention, the pharmaceutical excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and / or release retardants.
[0016] In one embodiment of the present invention, the dosage form of the targeted pharmaceutical composition is powder, tablet, granule, capsule, solution, emulsion, suspension, aerosol, ointment, suppository, lotion or injection.
[0017] The present invention also provides the use of the above-mentioned targeted drug composition in preparing drugs for preventing and / or treating lung cancer.
[0018] In one embodiment of the present invention, the lung cancer includes non-small cell lung cancer; the non-small cell lung cancer includes HER2-positive non-small cell lung cancer.
[0019] The technical solution of the present invention has the following advantages:
[0020] The present invention provides a targeted drug composition for preventing and / or treating lung cancer, wherein the components of the targeted drug composition include pyrotinib and erdafitinib. Experiments show that pyrotinib treatment can significantly induce phosphorylation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells, thereby activating them, and erdafitinib can inhibit the activation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells by inhibiting the phosphorylation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells, thereby increasing the sensitivity of HER2-positive non-small cell lung cancer cells to pyrotinib; experiments show that the combined use of pyrotinib and erdafitinib has a synergistic effect on inhibiting the proliferation of HER2-positive non-small cell lung cancer cells, and that the synergistic effect increases with the increase in the concentration of erdafitinib; at the same time, experiments show that compared with pyrotinib alone and erdafitinib alone, the combined use of pyrotinib and erdafitinib can more effectively inhibit tumor growth. Therefore, the targeted drug composition of pyrotinib and erdafitinib in combination has great application prospects in the preparation of a targeted drug composition for preventing and / or treating non-small cell lung cancer, especially HER2-positive non-small cell lung cancer.
[0021] Furthermore, in the targeted drug composition, the molar ratio of pyrotinib to erdafitinib is 1:1 to 1.25. Under this molar ratio, the targeted drug composition has a better effect in treating non-small cell lung cancer, especially HER2-positive non-small cell lung cancer.
[0022] Furthermore, in the targeted drug composition, the molar ratio of pyrotinib to erdafitinib is 1:1.25. Under this molar ratio, the targeted drug composition has a better effect in treating non-small cell lung cancer, especially HER2-positive non-small cell lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 : Effect of pyrotinib on the phosphorylation of membrane protein FGFR3 in HER2-positive non-small cell lung cancer cells. Figure 1 A: Expression of p-FGFR3 in H2170 and Calu-3 cells before and after treatment with pyrotinib alone or in combination with erdafitinib; B: Expression of p-FGFR3 in tumor tissues of H2170 and Calu-3 tumor-bearing mice before and after treatment with pyrotinib alone or in combination with erdafitinib. ** P<0.01vs. control group; ## P<0.01vs. pyrotinib group.
[0024] Figure 2 : Effects of pyrotinib combined with erdafitinib on proliferation of HER2-positive non-small cell lung cancer cells. Figure 2 A: Effects of pyrotinib and erdafitinib alone on the proliferation of H2170 cells; B: Effects of pyrotinib combined with erdafitinib on the proliferation of H2170 cells; C: Synergistic effect curve of pyrotinib combined with erdafitinib in inhibiting the proliferation of H2170 cells; D: Effects of pyrotinib and erdafitinib alone on the proliferation of Calu-3 cells; E: Effects of pyrotinib combined with erdafitinib on the proliferation of Calu-3 cells; F: Synergistic effect curve of pyrotinib combined with erdafitinib in inhibiting the proliferation of Calu-3 cells.
[0025] Figure 3 : Effects of pyrotinib combined with erdafitinib on tumor growth in tumor-bearing mice modeled with HER2-positive non-small cell lung cancer cells. Figure 3 In the figure, A: Effects of pyrotinib and erdafitinib on tumor growth in tumor-bearing mice derived from H2170 cell model; B: Effects of pyrotinib and erdafitinib on tumor growth in tumor-bearing mice derived from Calu-3 cell model. ** P<0.01. DETAILED DESCRIPTION
[0026] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0027] If no specific experimental steps or conditions are specified in the following examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.
[0028] Experimental Example 1: Pyrotinib induces FGFR3 receptor activation in HER2-positive non-small cell lung cancer cells
[0029] 1. Cell experiment
[0030] H2170 cells and Calu-3 cells (both H2170 cells and Calu-3 cells are HER2-positive non-small cell lung cancer cells, purchased from Wuhan Pronocell Life Science Co., Ltd.) were respectively cultured at 5×10 6 The inoculation amount of each well was inoculated into a 6-well plate with 1 mL of RPMI1640 medium (purchased from Pronocell) containing 10% (v / v) fetal bovine serum added to each well, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours. After 24 hours of culture, the wells of H2170 cells and Calu-3 cells were divided into a control group and a drug treatment group, respectively. After the grouping was completed, the original culture medium was aspirated with a sterile syringe, and 1 mL of RPMI1640 medium containing 10 μM (3 replicates) of pyrotinib was added to the wells of the H2170 drug treatment group and the Calu-3 drug treatment group, respectively, and continued to be cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 hours. The same amount of RPMI1640 medium was added to the wells of the H2170 control group and the Calu-3 control group as a control. After culturing for 24 hours, the cells were collected and the expression of FGFR3 receptor in H2170 cells and Calu-3 cells was detected by Western blot; wherein, the method of Western blot was as follows:
[0031] Pretreatment: Collect cells, extract total cell protein with RIPA lysis buffer (purchased from Beyotime), then take samples to measure protein concentration (BCA method, refer to the literature "Walker JM. The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol. 1994; 32: 5-8. doi: 10.1385 / 0-89603-268-X: 5."), add 1× SDS-PAGE protein loading buffer (purchased from Beyotime) according to the measured results to adjust the protein concentration to 2μg / μL, and obtain the pretreatment sample. Heat the pretreatment sample in a metal bath at 100℃ for 10min to obtain the protein sample to be tested. Label the protein sample to be tested and store it in a -20℃ refrigerator for use.
[0032] SDS-PAGE: Using a Western blot electrophoresis device, add freshly prepared MOPS-SDS Running Buffer (purchased from Nanjing Formase Biotechnology Co., Ltd.) to the inner and outer tanks. Add the quantitative protein sample and protein marker according to the experimental plan, connect the electrophoresis device, and run the electrophoresis at a constant voltage of 160V until the bromophenol blue reaches the appropriate position.
[0033] Transfer (wet transfer): prepare transfer solution, transfer clips, ice box and thick filter paper, activate PVDF membrane with methanol, gently peel off the glass plate, trim the glue according to the experimental requirements, and then transfer it to the PVDF membrane, and place it on the transfer clip according to the principle of black glue and white film. The molecular weight of the target molecule FGFR3 / p-FGFR3 is 130kDa, the constant current is 400mA, and the transfer time is 35 minutes.
[0034] Blocking: Place the wet-transferred PVDF membrane into a TM The cells were placed in a blocking box containing Western blocking solution (purchased from Bio-Tech Biotechnology Co., Ltd.) and blocked at room temperature (25°C) for 15 minutes.
[0035] Antibody incubation and development: Use the primary antibody diluent (purchased from Beyotime) to dilute the primary antibody FGFR3 (purchased from Abcam, model ab133644) and p-FGFR3 (purchased from Abcam, model ab155960) 1000 times to obtain the primary antibody working solution; use the primary antibody working solution to immerse the PVDF membrane and incubate at 4°C for 24 hours. After the incubation, the primary antibody was recovered and the membrane was washed three times with TBST working solution (purchased from Beyotime), each for 10 minutes. Use the secondary antibody diluent (purchased from Beyotime) to dilute the secondary antibody horseradish peroxidase-labeled goat anti-rabbit IgG (purchased from Beyotime, model A0208) 3000 times to obtain the secondary antibody working solution; use the secondary antibody working solution to immerse the PVDF membrane and incubate at room temperature (25°C) on a shaker (150rpm) for 1 hour. After the incubation, the secondary antibody was recovered and the membrane was washed three times with TBST working solution, each for 10 minutes. An ultrasensitive ECL chemiluminescence kit (purchased from Bio-Tech) was used, and the reagents in the kit were evenly dropped on the PVDF membrane for time gradient imaging.
[0036] Band gray value statistics: Image J was used for quantitative analysis of gray values; GraphPad Prism8 software was used for analysis and plotting. The analysis results are shown in Figure 1 A in.
[0037] 2. Animal experiments
[0038] H2170 cells and Calu-3 cells were resuspended in PBS buffer (purchased from Bio-Time) to a cell concentration of 3×10 7 / mL, and H2170 cell suspension and Calu-3 cell suspension were obtained. 20 BALB / c nude mice (4-5 weeks old, weighing 18-20g, purchased from Changzhou Cavens Experimental Animal Co., Ltd.) were randomly divided into two groups, the two groups were H2170 group and Calu-3 group, with 10 mice in each group. After the grouping was completed, 100μL of H2170 cell suspension was subcutaneously inoculated into the right axillary position of the H2170 group mice, and 100μL of Calu-3 cell suspension was subcutaneously inoculated into the right axillary position of the Calu-3 group mice. After the injection, the mice were put back into the cage and marked, and the status of the mice was observed every day. Wait until the mouse tumor reaches 100mm 3 At the same time, the H2170 group and the Calu-3 group were randomly divided into a control group and a drug treatment group, with 5 mice in each group. The mice in the H2170 drug treatment group and the Calu-3 drug treatment group were gavaged with pyrotinib at a dose of 10 mg / kg / day. Pyrotinib was dissolved in 100 μL of injection water and then gavaged. The H2170 control group and the Calu-3 control group were gavaged with the same amount of injection water as a control. After gavage for 21 days, the mice were dissected and tumor tissue sections were taken for immunohistochemical staining; wherein, the method of immunohistochemical staining is as follows:
[0039] Tumor tissues were fixed in 4% (w / v, g / 100 mL) paraformaldehyde for 24 h. After fixation, different concentrations of ethanol were prepared with n-butanol for dehydration, and dehydrated in 50% (v / v) ethanol for 2 h, 80% ethanol for 3 h, 65% ethanol for 1.5 h, 50% ethanol for 1 h, 30% ethanol for 4 h, 10% ethanol for 4 h, and pure n-butanol for 24 h. The dehydrated tumor tissues were first immersed in wax at 65°C for 4 h, then embedded in paraffin and sliced (6 μm). After the slides were dewaxed, they were first repaired with a universal strong antigen repair solution (purchased from Beyotime Biotechnology Co., Ltd.), and then blocked with an immunostaining blocking solution (purchased from Beyotime Biotechnology Co., Ltd.). The slides were first incubated with the primary antibody (p-FGFR3 antibody, the antibody was diluted 200 times with antibody diluent and used as the working solution, the antibody was purchased from Abcam, and the antibody diluent was purchased from Beyotime Biotechnology Co., Ltd.) working solution at 4°C for 18 h, and then incubated with the secondary antibody (horseradish peroxidase-labeled goat anti-rabbit IgG, the antibody was diluted to a concentration of 1000 times with antibody diluent and used as the working solution, the secondary antibody and antibody diluent were purchased from Beyotime Biotechnology Co., Ltd.) working solution at 25°C for 30 min, and then developed with DAB colorimetric solution (purchased from Wenzhou Maixin Biotechnology Development Co., Ltd.), followed by counterstaining with hematoxylin (purchased from Shanghai Beyotime Biotechnology Co., Ltd.), and finally dehydrated, transparent, and sealed. The results of immunohistochemistry (IHC) analysis are shown in Figure 1 B in.
[0040] according to Figure 1 The Western blot results in Figure A show that pyrotinib treatment can significantly induce phosphorylation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells, leading to their activation. Figure 1 The immunohistochemical staining results of Figure B show that p-FGFR3 expression is increased in the tumor tissue of the pyrotinib gavage group, which further confirms that pyrotinib treatment can significantly induce phosphorylation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells, causing their activation. On this basis, previous studies have shown that activation of bypass pathways may be one of the reasons that affect the anti-tumor activity of targeted drugs, and effectively preventing bypass pathway activation caused by targeted drugs may be a feasible strategy to improve efficacy. Therefore, based on the above results, it is speculated that inhibiting the activation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells can increase the anti-tumor activity of pyrotinib, a targeted drug.
[0041] Experimental Example 2: Erdafitinib combined with pyrotinib can improve the sensitivity of HER2-positive non-small cell lung cancer to pyrotinib
[0042] 1. Cell experiment
[0043] H2170 cells and Calu-3 cells were cultured at 1×10 5 The cells were inoculated into 96-well plates with 100 μL of RPMI1640 medium containing 10% (v / v) fetal bovine serum per well, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 h. After 24 h of culture, the wells of H2170 cells and Calu-3 cells were divided into the pyrotinib treatment group, the erdafitinib treatment group, and the combination treatment group. After grouping, the original culture medium was aspirated with a sterile syringe, and 100 μL of RPMI1640 culture medium containing different concentrations (0 μM, 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM, 6 replicate wells for each concentration) of pyrotinib was added to the wells of the H2170 pyrotinib group and the Calu-3 pyrotinib group, respectively. RPMI1640 medium containing erdafitinib at different concentrations (0 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM, with 6 replicate wells for each concentration) was added to the wells of the H2170 erdafitinib group and the Calu-3 erdafitinib group, respectively. 100 μL of RPMI1640 medium containing different concentrations of pyrotinib and different concentrations of erdafitinib (0 μM pyrotinib + 0 μM erdafitinib, 10 μM pyrotinib + 0 μM erdafitinib, 10 μM RPMI1640 medium containing pyrotinib + 7.5 μM erdafitinib, 10 μM pyrotinib + 10 μM erdafitinib, and 10 μM pyrotinib + 12.5 μM erdafitinib) was added to the wells of the H2170 combination group and the Calu-3 combination group, respectively, and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 24 h; after 24 h of culture, MTT reagent (purchased from Beyotime) was added to each well at an amount of 20 μL. The cells were incubated in a 96-well plate at 37°C in the dark for 4 h. After incubation, the liquid in the wells was aspirated with a sterile syringe, and dimethyl sulfoxide (DMSO) was added to the 96-well plate at a volume of 150 μL per well, and the mixture was shaken and mixed. After mixing, the OD value of each group was detected at a wavelength of 490 nm using an ELISA reader, and the cell survival rate was calculated to evaluate the cytotoxicity of erdafitinib and pyrotinib at different concentration ratios on non-small cell lung cancer cells (H2170 and Calu-3). The experimental results are shown in Figure 2 A in Figure 2 B and Figure 2 D in Figure 2E in the figure; the cell survival rate was calculated as follows: cell survival rate (%) = [(OD value of the experimental group - OD value of the blank group) / (OD value of the control group - OD value of the blank group)] × 100%. Based on the calculated cell survival rate, the inhibition rate of single drug and combined drug on cells was statistically analyzed (inhibition rate = 100 - cell survival rate), and the CI value (the combination index) was calculated using SynergyFinder package 20 software. The experimental results are shown in Figure 2 B and Figure 2 D in (CI value less than 1 indicates that the drug combination has synergistic effect, and the smaller the CI value, the stronger the synergistic effect between the drugs).
[0044] like Figure 2 A in Figure 2 B and Figure 2 D in Figure 2 As shown in Figure E, before combined with Erdafitinib, the treatment with Pyrotinib can reduce the viability of H2170 cells and Calu-3 cells. After combined with Erdafitinib, the effect of Pyrotinib treatment on reducing the viability of H2170 cells and Calu-3 cells is more significant. It can be seen that Erdafitinib can significantly increase the sensitivity of HER2-positive non-small cell lung cancer cells to Pyrotinib.
[0045] like Figure 2 C and Figure 2 As shown in F, in H2170 cells, the CI value of the combined action of pyrotinib (10 μM) and erdafitinib (7.5 μM) was 1.61, the CI value of the combined action of pyrotinib (10 μM) and erdafitinib (10 μM) was 0.83, and the CI value of the combined action of pyrotinib (10 μM) and erdafitinib (12.5 μM) was 0.28; in Calu-3 cells, the CI value of the combined action of pyrotinib (10 μM) and erdafitinib (7.5 μM) was 1.07, the CI value of the combined action of pyrotinib (10 μM) and erdafitinib (10 μM) was 0.72, and the CI value of the combined action of pyrotinib (10 μM) and erdafitinib (12.5 μM) was 0.32. It can be seen that when pyrotinib (10 μM) and erdafitinib (10 μM) were used, the combination therapy began to have a synergistic effect on inhibiting the proliferation of HER2-positive non-small cell lung cancer cells. As the concentration of erdafitinib increased, the synergistic effect increased (manifested by a further decrease in the CI value). Continuing to increase the concentration of erdafitinib may further increase the synergistic effect, but the corresponding toxic side effects may be more significant. Therefore, the lowest effective concentration ratio (i.e., the molar ratio of pyrotinib and erdafitinib is 1:1.25) was used to carry out the corresponding animal experiments.
[0046] 2. Animal experiments
[0047] H2170 cells and Calu-3 cells were resuspended in PBS buffer to a cell concentration of 3×10 7 / mL, and H2170 cell suspension and Calu-3 cell suspension were obtained. 40 BALB / c nude mice (4-5 weeks old, weighing 18-20g, purchased from Changzhou Cavens Experimental Animal Co., Ltd.) were randomly divided into two groups, the two groups were H2170 group and Calu-3 group, with 20 mice in each group. After the grouping was completed, 100μL of H2170 cell suspension was subcutaneously inoculated into the right axillary position of the H2170 group mice, and 100μL of Calu-3 cell suspension was subcutaneously inoculated into the right axillary position of the Calu-3 group mice. After the injection, the mice were put back into the cage and marked, and the status of the mice was observed every day. Wait until the mouse tumor reaches 100mm 3 The two groups of mice were randomly divided into four groups, namely, control group, pyrotinib group, erdafitinib group and pyrotinib+erdafitinib group, with 5 mice in each group. After the grouping was completed, eight groups of mice were gavaged separately; among them, two groups of pyrotinib group mice were gavaged with pyrotinib at a dose of 10 mg / kg / day, and pyrotinib was dissolved in 100 μL of water for injection before gavage; two groups of erdafitinib group mice were gavaged with erdafitinib at a dose of 12.5 mg / kg / day, and erdafitinib was dissolved in 100 μL of water for injection before gavage; two groups of pyrotinib + erdafitinib groups were gavaged with pyrotinib and erdafitinib at the same time, with a dose of 10 mg / kg / day for pyrotinib and a dose of 12.5 mg / kg / day for erdafitinib, and pyrotinib and erdafitinib were simultaneously dissolved in 100 μL of water for injection before gavage; two control groups were gavaged with an equal amount of water for injection as a control. During the gavage period, the weight and tumor size of the mice were measured every two days, and the measurement results are shown in the table. Figure 3 A and Figure 3 B in the figure; where tumor volume = (long diameter × short diameter 2 ) / 2. After 21 days of intragastric administration, the mice were dissected and tumor tissue sections were taken for immunohistochemical staining according to the method in Experimental Example 1. The results of immunohistochemical IHC analysis are shown in Figure 1 B in.
[0048] like Figure 3 A and Figure 3 As shown in B, in the H2170 tumor group, the tumor volumes at the end of the experiment were: control group 1037±130mm 3 , pyrotinib group 553±145mm 3 , Erdafitinib group 782±114mm 3 , pyrotinib + erdafitinib group 230±59mm 3Among them, the tumor volumes of the pyrotinib + erdafitinib group were 77.82%, 58.41% and 70.58% smaller than those of the other three groups, respectively; in the Calu-3 tumor group, the tumor volumes at the experimental endpoints were: 1342±146mm in the control group 3 , pyrotinib group 623±157mm 3 , 878±117mm in the erdafitinib group 3 , pyrotinib + erdafitinib group 326±46mm 3 , among which, the pyrotinib + erdafitinib group was 75.71%, 47.67% and 62.87% smaller than the other three groups, respectively. It can be seen that the tumor volume of the combination drug group was significantly smaller than that of the pyrotinib or erdafitinib single drug group, which shows that the combination drug can more effectively inhibit tumor growth.
[0049] like Figure 1 As shown in Figure B, compared with the pyrotinib monotherapy group, the p-FGFR3 expression in tumor tissues was significantly reduced after the combined treatment with pyrotinib and erdafitinib. It can be seen that erdafitinib can inhibit the phosphorylation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells and then inhibit the activation of FGFR3 receptors in HER2-positive non-small cell lung cancer cells, thereby increasing the sensitivity of HER2-positive non-small cell lung cancer cells to pyrotinib. This result further confirms that combined drug therapy can more effectively inhibit tumor growth.
[0050] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the present invention.
Claims
1. A targeted drug composition for preventing and / or treating lung cancer, characterized in that: The components of the targeted drug composition include pyrotinib and erdafitinib.
2. The targeted drug composition according to claim 1, characterized in that In the targeted drug composition, the molar ratio of pyrotinib to erdafitinib is 1:1 to 1.
25.
3. The targeted drug composition according to claim 1 or 2, characterized in that: In the targeted drug composition, the molar ratio of pyrotinib to erdafitinib is 1:1.
25.
4. The targeted drug composition according to any one of claims 1 to 3, characterized in that: The lung cancer includes non-small cell lung cancer; the non-small cell lung cancer includes HER2-positive non-small cell lung cancer.
5. The targeted drug composition according to any one of claims 1 to 4, characterized in that: The prevention and / or treatment of lung cancer includes increasing the sensitivity of lung cancer cells to pyrotinib, inhibiting the proliferation of lung cancer cells and / or inhibiting the growth of lung tumors.
6. The targeted drug composition according to claim 5, characterized in that The method of increasing the sensitivity of lung cancer cells to pyrotinib includes inhibiting the activation of FGFR3 receptors in lung cancer cells; and the method of inhibiting the activation of FGFR3 receptors in lung cancer cells includes inhibiting the phosphorylation of FGFR3 receptors in lung cancer cells and thereby inhibiting the activation of FGFR3 receptors in lung cancer cells.
7. The targeted drug composition according to any one of claims 1 to 6, characterized in that: The components of the targeted drug composition include active components and pharmaceutical excipients; the active components consist of pyrotinib and erdafitinib.
8. The targeted drug composition according to claim 7, characterized in that: The pharmaceutical excipients include solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids and / or release retardants.
9. The targeted drug composition according to any one of claims 1 to 8, characterized in that: The dosage form of the targeted drug composition is powder, tablet, granule, capsule, solution, emulsion, suspension, aerosol, ointment, suppository, lotion or injection.
10. Use of the targeted drug composition according to any one of claims 1 to 9 in the preparation of a drug for preventing and / or treating lung cancer.
